Clinigence Holdings (NUTX) AI Stock Analysis

Compare

217 Followers

NUTX Dividends

Top Page

Clinigence Holdings

(NASDAQ:NUTX)

75Outperform

Nutex Health Inc. has demonstrated strong financial growth and improved profitability, highlighted by a significant increase in revenue and net income. The stock exhibits strong technical momentum, trading well above key moving averages, indicating a bullish trend. While the company is reasonably valued, the lack of a dividend yield may be a minor detraction for some investors. The earnings call further supports the positive outlook, with successful debt management and strategic expansion initiatives. However, high leverage and operational challenges related to the No Surprises Act could pose risks moving forward.

Positive Factors

Business Expansion

The company opened four new facilities in 2024, expanding its network to 24 micro-hospitals, demonstrating its growth and expansion strategy.

Financial Performance

Nutex Health Inc holds a strong cash position with cash significantly exceeding long-term debt.

Negative Factors

Market Valuation

Shares currently trade at an EV/revenue multiple of 0.4x our 2025 estimate, below the peer average of 1.6x, excluding NUTX.

Valuation Concerns

Shares currently trade at a discount to peers, reflecting the early stage and unproven nature of Nutex's business model.

Clinigence Holdings (NUTX) vs. S&P 500 (SPY)

Market Cap

$823.74M

Dividend YieldN/A

Average Volume (3M)98.75K

Price to Earnings (P/E)16.1

Beta (1Y)2.27

Revenue Growth93.80%

EPS GrowthN/A

CountryUS

Employees800

SectorHealthcare

Sector Strength66

IndustryMedical - Healthcare Information Services

Share Statistics

EPS (TTM)9.27

Shares Outstanding5,528,448

10 Day Avg. Volume166,639

30 Day Avg. Volume98,746

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)1.08

Price to Cash Flow (P/CF)11.70

P/FCF Ratio3.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$125.00

Price Target Upside-16.11% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Clinigence Holdings Business Overview & Revenue Model

Company DescriptionNutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.

How the Company Makes MoneyClinigence Holdings makes money primarily through the sale of its technology solutions to healthcare providers and organizations. The company's revenue model includes subscription-based fees for its software platforms, which offer analytics and population health management tools. Additionally, Clinigence may generate income through consulting services and partnerships with healthcare providers who seek to implement value-based care initiatives. These revenue streams are supported by the company's ability to deliver actionable insights and data-driven strategies that help healthcare organizations improve efficiency and patient outcomes.

Clinigence Holdings Financial Statement Overview

Summary

Clinigence Holdings has shown strong revenue growth and improved profitability with significant increases in total revenue and net income. However, high leverage and fluctuating EBIT and EBITDA margins pose financial risks. The company's cash flow position has improved with positive free cash flow, indicating better financial health.

Income Statement

Positive

The company's revenue has shown significant growth from 2019 to 2024, with a notable increase in Total Revenue in 2024 to $479.9 billion. Gross Profit Margin and Net Profit Margin have improved significantly from negative figures in 2023 to strong positive values in 2024, indicating improved operational efficiency and profitability. However, the EBIT and EBITDA margins have fluctuated, suggesting some instability in operational performance over the years.

Balance Sheet

Neutral

The Debt-to-Equity Ratio is relatively high, indicating significant leverage, which could pose financial risks. Despite this, the company has a strong equity base with a Stockholders' Equity of $201.9 billion in 2024. The Equity Ratio has improved over the years, suggesting better asset financing through equity rather than debt.

Cash Flow

Positive

Operating Cash Flow has been consistently positive, showing strong cash-generating capability. The Free Cash Flow turned positive in 2024, signaling an improvement in financial health. However, the Free Cash Flow Growth Rate fluctuated significantly in previous years, pointing to potential volatility in cash flow management.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
479.95M	247.65M	219.29M	331.53M	273.42M
	Gross Profit
196.26M	34.77M	13.45M	179.28M	271.60M
	EBIT
130.62M	-31.77M	-5.14M	170.26M	152.33M
	EBITDA
148.65M	-14.58M	-393.96M	183.45M	-5.12M
	Net Income Common Stockholders
52.18M	-45.79M	-432.74M	132.59M	105.97M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
43.58B	22.00M	34.26M	36.12M	25.51M
	Total Assets
655.32B	398.25M	431.75M	394.65M	308.55M
	Total Debt
314.28B	275.76M	267.20M	178.55M	150.12M
	Net Debt
270.70B	253.75M	232.95M	142.43M	124.61M
	Total Liabilities
453.43B	319.14M	311.42M	203.07M	161.19M
	Stockholders Equity
201.89B	61.45M	95.86M	114.65M	85.81M
Cash Flow		Free Cash Flow
23.15B	-8.24M	35.97M	136.51M	20.07M
	Operating Cash Flow
23.15B	1.26M	50.61M	173.43M	81.26M
	Investing Cash Flow
-2.67B	-11.24M	-4.34M	-36.98M	-61.19M
	Financing Cash Flow
1.09M	-2.27M	-48.13M	-125.85M	-2.56M

Clinigence Holdings Technical Analysis

Technical Analysis Sentiment

Positive

Last Price149.00

Price Trends

50DMA

67.52

Positive

100DMA

52.01

Positive

200DMA

35.11

Positive

Market Momentum

MACD

22.75

Negative

RSI

84.39

Negative

STOCH

95.08

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Positive. The current price of 149 is above the 20-day moving average (MA) of 87.26, above the 50-day MA of 67.52, and above the 200-day MA of 35.11, indicating a bullish trend. The MACD of 22.75 indicates Negative momentum. The RSI at 84.39 is Negative, neither overbought nor oversold. The STOCH value of 95.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUTX.

Clinigence Holdings Risk Analysis

Clinigence Holdings disclosed 62 risk factors in its most recent earnings report. Clinigence Holdings reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Clinigence Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUTX	75 Outperform	$823.74M	16.07	50.22%	―	93.80%	―
CMPX	60 Neutral	$241.99M	―	-36.07%	―	―	-7.93%
Sector *	51 Neutral	$5.19B	3.12	-41.08%	2.95%	17.98%	2.02%
ATYR	48 Neutral	$275.46M	―	-79.69%	―	-33.43%	8.94%
IVA	47 Neutral	$308.40M	―	344.74%	―	-47.32%	-26.67%
OLMA	46 Neutral	$302.03M	―	-39.07%	―	―	0.42%
CADL	32 Underperform	$215.87M	―	-139.56%	―	―	-33.79%

* Healthcare Sector Average

Performance Comparison

NUTX

Clinigence Holdings

149.00

142.11

2062.55%

ATYR

aTyr Pharma

3.10

1.46

89.02%

IVA

Inventiva

3.36

0.06

1.82%

CMPX

Compass Therapeutics

1.75

0.26

17.45%

OLMA

Olema Pharmaceuticals

4.42

-5.45

-55.22%

CADL

Candel Therapeutics

4.57

-0.97

-17.51%

Clinigence Holdings Earnings Call Summary

Earnings Call Date: Mar 31, 2025 | % Change Since: 216.82% | Next Earnings Date: May 19, 2025

Earnings Call Sentiment Positive

The call highlighted strong financial growth, successful arbitration outcomes, and effective debt management, despite challenges posed by the No Surprises Act and the operational burden of the arbitration process.

Highlights

Exceptional Revenue Growth

For the full year of 2024, total revenue reached $479.9 million, up 94% from $247.6 million in 2023.

Significant EBITDA Increase

Adjusted EBITDA increased from $10.8 million in 2023 to $123.7 million in 2024, up over 1,000%.

Net Income Turnaround

Full year 2024 net income was $52 million compared to a loss of $46 million in 2023.

Hospital Expansion

Opened four new hospitals in 2024, bringing the total to 24 hospitals across 11 states.

Debt Management

Long-term debt decreased from $26 million in 2023 to $22 million in 2024, emphasizing fiscal responsibility.

Arbitration Process Success

Achieved an 80% win rate in arbitration, resulting in significant revenue recovery, with a 150% to 250% increase in reimbursement on the facility collection side.

Lowlights

Impact of No Surprises Act

The flawed implementation of the No Surprises Act and its arbitration process has hit revenue per patient reimbursement hard, with insurer payments for emergency services dropping roughly 30% in 2022.

Arbitration Process Challenges

The arbitration process is costly, labor-intensive, and time-consuming, posing a significant operational challenge.

Company Guidance

During the Nutex Health Fourth Quarter 2024 Earnings Call, significant financial metrics were highlighted, demonstrating the company's robust performance. Total revenue for the full year reached $479.9 million, marking a 94% increase from 2023's $247.6 million. The adjusted EBITDA saw an impressive surge from $10.8 million in 2023 to $123.7 million in 2024, reflecting a growth of over 1,000%. Net income also improved, reaching $52 million in 2024, compared to a loss of $46 million the previous year. Patient volume rose by 17%, with total hospital visits increasing from 144,000 in 2023 to 168,000 in 2024, driven by a 6.5% growth from mature hospitals. Despite opening four new hospitals, long-term debt was efficiently managed, increasing only slightly in the current portion from $10.8 million in 2023 to $14 million in 2024, while net long-term debt decreased from $26 million to $22 million. These metrics underscore Nutex Health's successful expansion strategy and fiscal discipline amidst challenges like the No Surprises Act and its arbitration process.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.